Indirect recognition of allo MHC peptides - Potential role in human transplantation

Nephrology Dialysis Transplantation

Volumn 14, Issue 1, 1999, Pages 8-11

  Watschinger, Bruno ^a,b  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN;

ALLOIMMUNITY; GRAFT REJECTION; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; SHORT SURVEY;

GRAFT REJECTION; HUMANS; ISOANTIGENS; MAJOR HISTOCOMPATIBILITY COMPLEX; T-LYMPHOCYTES; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS;

EID: 0032944192     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/14.1.8     Document Type: Short Survey

References (29)

1. Cecka JM, Terasaki PI. The UNOS scientific renal transplant registry. In: Terasaki PI, ed. Clinical transplants. Los Angeles: UCLA Tissue Typing Laboratory 1995; 1-18
2. Tullius SG, Tilney NL. Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation 1995; 59: 313-318
3. Krensky AM. The HLA system, antigen processing and presentation. Kidney Int 1997; 51 [Suppl 58]: S2-S7
4. Sayegh MH, Watschinger B, Carpenter CB. Mechanisms of T cell recognition of alloantigen: the role of peptides. Transplantation 1994; 57: 1295-1302
5. Lechler R, Batchelor J. Immunogenicity of retransplanted rat kidney allografts. J Exp Med 1982; 156: 1835-1841
6. Watschinger B. How T cells recognize alloantigen: evidence for two pathways of allorecognition. Nephrol Dial Transplant 1995; 10: 1556-1558
7. Shoskes DA, Wood KJ. Indirect presentation of MHC antigens in transplantation. Immunol Today 1994; 15: 32-38
8. de-Koster HS, Anderson DE, Termitjelen A. T cells sensitized to synthetic HLA-DR3 peptide give evidence of continuous presentation of denatured HLA-DR3 molecules. J Exp Med 1989; 169: 1191-1196
9. Liu Z, N. B, Suciu-Foca N. T cell recognition of allopeptides in context of syngeneic MHC. J Immunol 1992; 148: 35-40
10. Liu Z, Sun YK, Xi YP, Maffei A, Reed E, Harris P, Suciu-Foca N. Contribution of direct and indirect allorecognition pathways to T-cell alloreactivity. J Exp Med 1993; 177: 1643-1650
11. Zavazava N, Stegmann S, Freese A, Muller-Ruchholtz W. Recognition of HLA-derived peptides in transplant patients. Transplant Proc 1995; 27: 489-490
12. Susskind B, lannotti MR, Shornick MD, Steward NS, Gorka J, Mohankumar T. Indirect allorecognition of HLA class I peptides by CD4+ cytolytic T lymphocytes. Hum Immunol 1996; 46: 1-9
13. Watschinger B, Gallon L, Carpenter CB, Sayegh MH. Mechanisms of allorecognition: recognition by in vivo primed T-cells of specific major histocompatibility complex polymorphisms presented as peptides by responder antigen-presenting cells. Transplantation 1994; 57: 572-576
14. Fangmann J, Dalchau R, Sawyer G, Priestly CA, Faber JW. T cell recognition of donor major histocompatibility complex class I peptides during allograft rejection. Eur J Immunol 1992; 22: 1525-1530
15. Benichou G, Takizawa AP, Olson AC, McMillan M, Sercarz EE. Donor major histocompatibility complex (MHC) peptides are presented by recipient MHC molecules during graft rejection. J Exp Med 1992; 175: 305-308
16. Liu Z, Colovai AI, Tugulea S et al. Indirect recognition of donor HLA-DR peptides in organ allograft rejection. J Clin Invest 1996; 98: 1150-1157
17. van Besouw NM, Vaessen LM, Daane CR, et al. Peripheral monitoring of direct and indirect alloantigen presentation pathways in clinical heart transplant recipients. Transplantation 1996; 61: 165-167
18. Saleem M, Gustafsson K, Fabre JW. Attempts to demonstrate indirect T cell allorecognition of donor MHC peptides in transplant patients. Immunol Lett 1996; 54: 21-24
19. Gallon L, Watschinger B, Murphy B, Akalin E, Sayegh MH, Carpenter CB. The indirect pathway of allorecognition. The occurrence of self-restricted T cell recognition of allo-MHC peptides early in acute renal allograft rejection and its inhibition by conventional immunosuppression. Transplantation 1995; 59: 612-616
20. Liu Z, Harris PE, Colovai AI, Reed EF, Maffei A, Suciu-Foca N. Indirect recognition of donor MHC class II antigens in human transplantation. Clin Immunol Immunopath 1996; 78: 228-235
21. Mason PD, Robinson CM, Lechler RI. Detection of donor-specific hyporesponsiveness following late failure of human renal allografts. Kidney Int 1996; 50: 1019-1025
22. Reed EF, Hong B, Ho E, Harris PE, Weinberger J, Suciu-Foca N. Monitoring of soluble HLA alloantigens and anti-HLA antibodies identifies heart allograft recipients at risk of transplant-associated coronary artery disease. Transplantation 1996; 61: 566-572
23. Vella JP, Spadfora-Ferreira M, Murphy B, et al. Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction. Transplantation 1997; 6: 795-800
24. Ciubotariu R, Liu Z, Colovai AI, et al. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest 1998; 101: 398-405
25. Sayegh MH, Carpenter CB. Role of indirect allorecognition in allograft rejection. Intern Rev Immunol 1996; 13: 221-229
26. Chitilian HV, Auchincloss Jr. H. The indirect pathway in graft rejection. Curr Opin Organ Transplant 1997; 2: 3-7
27. Magee CC, Sayegh MH. Peptide-mediated immunosuppression. Curr Opin Immunol 1997; 9: 669-675
28. Benichou G, Tam RC, Soares LRB, Fedoseyeva V. Indirect T-cell allorecognition: perspectives for peptide-based therapy in transplantation. Immunol Today 1997; 18: 67-71
29. Giral M, Cuturi MC, Nguyen JM. et al. Decreased cytotoxic activity of natural killer cells in kidney allograft recipients treated with human HLA-derived peptide. Transplantation 1997; 63: 1004-1011